^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Leiomyosarcoma
    Drug:doxorubicin hydrochloride (Topoisomerase II inhibitor) +
    dacarbazine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/29/2022
    Excerpt:
    Soft Tissue Sarcoma...Other Recommended Regimens...AD LMS only (doxorubicin, dacarbazine) - if ifosfamide is not considered appropriate